Skip to Accessibility Tools Skip to Content Skip to Footer

High-dose statin therapy reduces brain atrophy in Secondary Progressive MS, new study finds

Headlines regarding the use of statins, or cholesterol-lowering drugs, in multiple sclerosis has once again hit the newsstands after The Lancet published results from a new study on March 19, 2014.  In the current study, “Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial,” researchers noted a 43% reduced annualized rate of brain atrophy in SPMS patients taking 80mg simvastatin vs placebo over a 2-year time period (Chataway, 2014).  This study appears to be the first conducted specifically in SPMS, a form of the disease which is characterized more by brain atrophy than RRMS which involves primarily CNS inflammation.

For the past decade, small preliminary studies have suggested that statins may be helpful as a disease-modifying treatment or add-on therapy for patients living with MS or  those who have experienced a first neurological event.  Early results were promising and suggest that MS patients who also take statins have less nerve damage over time. A study in 64 patients with acute optic neuritis showed that simvastatin improved visual outcomes (Tsakiri, 2012).  Researchers have demonstrated that statin drugs, such as simvastatin, inhibit IL-17 cytokines and Th17 cell differentiation in patients with MS (Zhang, 2008, 2011, 2013).  Other research has demonstrated that lovastatin can be used to regulate vitamin D metabolism and improve vitamin D3 efficacy in animal models of MS (Paintlia, 2012) which may have implications for future clinical research.

Statins as Add-On Therapy in RRMS:

However, beginning with a small study in 2008, MS patients treated with atorvastatin (Lipitor) seemed to get worse. Ten of the 17 patients who received either 40 mg or 80 mg of atorvastatin had either a relapse or a new lesion on MRI as compared to only 1 of 9 patients taking placebo who experienced a relapse or had active lesions on MRI.  Authors concluded that atorvastatin (40 mg or 80 mg) taken with interferon beta-1a (Rebif) worsened MS (Lock, 2008).

A study involving 77 patients found that 40mg atorvastatin in addition to interferon beta-1b (Betaseron) did not have a beneficial effect on relapsing-remitting MS compared to interferon beta-1b monotherapy over a 12-month period (Kamm, 2012).  In a larger placebo-controlled, double-blind, randomized study involving 307 patients found no beneficial effect of adding 80mg simvastatin to interferon beta-1a (Avonex) vs placebo.  In fact, disease measures such as annualized relapse rate, time to first relapse, and number of new or enlarging T2 lesions were slightly worse (Sorensen, 2011).  A retrospective study found that disability progression did not differ significantly between MS patients using statin therapy vs controls. Researchers found that statins, in doses currently prescribed for lowering cholesterol, do not affect the long-term course of MS (Paz Soldán, 2012).

In vitro studies have revealed that high-dose add-on statin therapy significantly reduces interferon-beta function and inhibits the effectiveness of interferon beta-1 therapies in RRMS patients (Feng, 2012).  Post hoc analysis of patients in the SENTINEL trial indicated that statin therapy did not appear to affect the clinical effects of interferon beta-1a (Avonex) in patients with RRMS (Rudick, 2009) and early studies supported the safety and efficacy of simvastatin in RRMS pateints (Paul, 2008; Togha, 2010). MS patients in the ACTIVE trial (Atorvastatin Combined To Interferon to Verify the Efficacy) who took atorvastatin (20mg) in addition to Rebif (interferon beta-1a) had significantly fewer gadolinium-enhanced lesions after 24 months of treatment versus baseline and significantly fewer relapses.  The MS patients who only received Rebif experienced a slightly elevated risk for a 1-point EDSS increase after 24 months (Lanzillo, 2010).

Statins, Oligodendrocytes, and Remyelination:

Some studies suggest that drugs such as lovastatin or simvastatin may interfere with the remyelination process in patients with MS which is initiated by recruitment and differentiation of oligodendrocyte progenitor cells (OPCs) into myelinating oligodendrocytes. Simvastatin inhibits central nervous system remyelination by blocking progenitor differentiation (Miron, 2009; Klopfleisch, 2008; Smolders, 2010). Primary oligodendrocytes treated with lovastatin formed membrane sheets which were devoid of the major myelin proteins including myelin basic protein (Maier, 2009).  However, another group of researchers found that lovastatin accelerated the differentiation of OPCs (Paintlia, 2010, 2008).

This all leaves me wondering whether the simvastatin I take to lower my LDL cholesterol levels may be helping my MS or hindering it.  That’s a question which cannot be answered at this time but I seem to be doing well.  At least I am positive that the level of “bad” cholesterol has been effectively reduced by treatment and that my cardiovascular system is healthy.

Lisa Emrich | Follow me on Facebook |Follow me on Twitter | Follow me on Pinterest

This article represents the opinions, thoughts, and experiences of the author; none of this content has been paid for by any advertiser. The team does not recommend or endorse any products or treatments discussed herein. Learn more about how we maintain editorial integrity here.

  1. Chataway J, Schuerer N, Alsanousi A, et al. Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial. The Lancet, Early Online Publication, 19 March 2014. doi:10.1016/S0140-6736(13)62242-4
  2. Feng X, Han D, et al. Inhibition of interferon-beta responses in multiple sclerosis immune cells associated with high-dose statins. Arch Neurol. 2012 Oct;69(10):1303-9.
  3. Kamm CP, El-Koussy M, et al. Atorvastatin added to interferon β for relapsing multiple sclerosis: a randomized controlled trial. J Neurol. 2012 Nov;259(11):2401-13. doi: 10.1007/s00415-012-6513-7. Epub 2012 May 9.
  4. Klopfleisch S, Merkler D et al. Negative impact of statins on oligodendrocytes and myelin formation in vitro and in vivo. J Neurosci. 2008 Dec 10;28(50):13609-14. doi: 10.1523/JNEUROSCI.2765-08.2008.
  5. Lanzillo R, Orefice G, et al. Atorvastatin combined to interferon to verify the efficacy (ACTIVE) in relapsing-remitting active multiple sclerosis patients: a longitudinal controlled trial of combination therapy. Mult Scler. 2010 Apr;16(4):450-4. doi: 10.1177/1352458509358909. Epub 2010 Feb 11.
  6. Lock, Christopher.  “Are "statins" beneficial or harmful in multiple sclerosis?”  Neurology 2008;71:e54-e56.
  7. Maier O, De Jonge, J, Nomden A, Hoekstra D, Baron W. Lovastatin induces the formation of abnormal myelin-like membrane sheets in primary oligodendrocytes. Glia. 2009 Mar;57(4):402-13. doi: 10.1002/glia.20769.
  8. Miron VE, Zehntner SP, et al. Statin therapy inhibits remyelination in the central nervous system. Am J Pathol. 2009 May;174(5):1880-90. doi: 10.2353/ajpath.2009.080947. Epub 2009 Apr 6.
  9. Paintlia AS, Paintlia MK, Singh AK, Orak JK, Singh I. Activation of PPAR-γ and PTEN cascade participates in lovastatin-mediated accelerated differentiation of oligodendrocyte progenitor cells. Glia. 2010 Nov 1;58(14):1669-85. doi: 10.1002/glia.21039.
  10. Paintlia AS, Paintlia MK, Singh AK, Singh I. Inhibition of rho family functions by lovastatin promotes myelin repair in ameliorating experimental autoimmune encephalomyelitis. Mol Pharmacol. 2008 May;73(5):1381-93. doi: 10.1124/mol.107.044230. Epub 2008 Jan 31.
  11. Paul F, Waiczies S, et al. Oral high-dose atorvastatin treatment in relapsing-remitting multiple sclerosis. PLoS One. 2008 Apr 9;3(4):e1928. doi: 10.1371/journal.pone.0001928.
  12. Paz Soldán MM, Pittock SJ, Weigand SD, Yawn BP, Rodriguez M. Statin therapy and multiple sclerosis disability in a population-based cohort. Mult Scler. 2012 Mar;18(3):358-63. doi: 10.1177/1352458511421920. Epub 2011 Sep 9.
  13. Rudick RA, Pace A, et al. Effect of statins on clinical and molecular responses to intramuscular interferon beta-1a. Neurology. 2009 Jun 9;72(23):1989-93. doi: 10.1212/WNL.0b013e3181a92b96.
  14. Smolders I, Smets I, Maier O, vandeVen M, Steels P, Ameloot M. Simvastatin interferes with process outgrowth and branching of oligodendrocytes. J Neurosci Res. 2010 Nov 15;88(15):3361-75. doi: 10.1002/jnr.22490.
  15. Sorensen PS, Lycke J, et al. Simvastatin as add-on therapy to interferon β-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial. Lancet Neurol. 2011 Aug;10(8):691-701. doi: 10.1016/S1474-4422(11)70144-2.
  16. Togha M, Karyigh SA, et al. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial. Mult Scler. 2010 Jul;16(7):848-54. doi: 10.1177/1352458510369147. Epub 2010 May 20.
  17. Tsakiri A, Kallenbach K, Fuglø D, Wanscher B, Larsson H, Frederiksen J. Simvastatin improves final visual outcome in acute optic neuritis: a randomized study. Mult Scler. 2012 Jan;18(1):72-81. doi: 10.1177/1352458511415452. Epub 2011 Sep 15.
  18. Zhang X, Jin J, Peng X, Ramgolam VS, Markovic-Plese S. Simvastatin inhibits IL-17 secretion by targeting multiple IL-17-regulatory cytokines and by inhibiting the expression of IL-17 transcription factor RORC in CD4+ lymphocytes. J Immunol. 2008 May 15;180(10):6988-96.
  19. Zhang X, Tao Y, Troiani L, Markovic-Plese S. Simvastatin inhibits IFN regulatory factor 4 expression and Th17 cell differentiation in CD4+ T cells derived from patients with multiple sclerosis. J Immunol. 2011 Sep 15;187(6):3431-7. doi: 10.4049/jimmunol.1100580. Epub 2011 Aug 19.
  20. Zhang X, Tao Y, Wang J, Garcia-Mata R, Markovic-Plese S. Simvastatin inhibits secretion of Th17-polarizing cytokines and antigen presentation by DCs in patients with relapsing remitting multiple sclerosis. Eur J Immunol. 2013 Jan;43(1):281-9. doi: 10.1002/eji.201242566. Epub 2012 Dec 6.


  • RichG
    5 years ago

    you have bigger problems than wondering if statins are helping your MS. You have to worry about what good the statins do at all and why your doctor had fallen prey to the Big Pharma statin propaganda machine.

  • Poll